GKSL
Gujarat Kidney And Super Speciality share price & financials
- Price
- ₹128.36
- Market cap
- ₹1.3k Cr
- Sector
- Healthcare
Quarterly results
Q1 FY27: revenue down 19.3%, net profit down 47.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 9 | 9 | 8 | 11 | 10 +2% | 10 +15% | 9 +15% | 9 −19% |
| EBITDA | 5 | 4 | 2 | 6 | 4 −16% | 4 +9% | 2 −32% | 3 −53% |
| Net profit | 3 | 2 | 1 | 4 | 2 −22% | 2 +5% | 1 +9% | 2 −48% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +65.4% YTD
YTD: ₹103.44 on 1 Jan 2026 → ₹171.09. High ₹176.34 (7 Sept 2026), low ₹99.36 (23 Jan 2026).
Financials, as filed
| Year ending | FY26 |
|---|---|
| Revenue | ₹40 Cr |
| Operating profit | ₹16 Cr |
| Operating margin | 40.3% |
| Interest | ₹1 Cr |
| Depreciation | ₹3 Cr |
| Net profit | ₹10 Cr |
| Net margin | 24.7% |
| Cash from operations | ₹-7 Cr |
| Free cash flow | ₹-8 Cr |
| ROCE | 9.3% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Equity capital | ₹0 Cr | ₹0 Cr | ₹11 Cr | ₹16 Cr |
| Reserves | ₹0 Cr | ₹11 Cr | ₹22 Cr | ₹231 Cr |
| Borrowings | ₹0 Cr | ₹2 Cr | ₹20 Cr | ₹16 Cr |
| Other liabilities | ₹4 Cr | ₹4 Cr | ₹23 Cr | ₹4 Cr |
| Total liabilities | ₹4 Cr | ₹17 Cr | ₹76 Cr | ₹266 Cr |
| Fixed assets | ₹3 Cr | ₹10 Cr | ₹29 Cr | ₹26 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹109 Cr |
| Other assets | ₹1 Cr | ₹7 Cr | ₹46 Cr | ₹132 Cr |
| Total assets | ₹4 Cr | ₹17 Cr | ₹76 Cr | ₹266 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Dec 2025, the public added +6.70 pp while FIIs trimmed −5.58 pp. The shareholder count shrank 34% to 18,301.
- Promoters
- 71.5%
- FIIs
- 4.9%
- DIIs
- 0.6%
- Public
- 23.1%
Since Dec 2025
- Public +6.70 pp
- FIIs −5.58 pp
- DIIs −1.11 pp
How it drifted, 3 quarters
Over this window the public went from 16.4% to 23.1% — +6.7 pp.
Ownership split by quarter, oldest first. Dec '25: Promoters 71.5%, FIIs 10.5%, DIIs 1.7%, Public 16.4%.Mar '26: Promoters 71.5%, FIIs 4.9%, DIIs 0.6%, Public 23.1%.Jun '26: Promoters 71.5%, FIIs 4.9%, DIIs 0.6%, Public 23.1%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Gujarat Kidney And Super Speciality Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Pragnesh Yashwantsinh Bharpoda | 38.16% | unchanged |
| Anitaben Nayak | 11.10% | unchanged |
| Yashwantsingh Motisingh Bharpoda | 11.10% | unchanged |
| Bhartiben Pragnesh Bharpoda | 11.10% | unchanged |
| Khandelwal Finance Private Limited | 1.67% | unchanged |
| Craft Emerging Market Fund Pcc-Citadel Capital Fund FPI fund | 1.67% | unchanged |
| Sumanben K Padwal | 0.00% | unchanged |
| Hitendrasinh K Padwal | 0.00% | unchanged |
| Tikamsinh Bharpoda | 0.00% | unchanged |
| Chatrasinh Bharpoda | 0.00% | unchanged |
| Sampatben S Khasariya | 0.00% | unchanged |
| Vihan Bharpoda | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 59.9% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse Gujarat Kidney And Super Speciality Limited
Guides on how to read this kind of business and the numbers that matter.